Nosiheptide Harbors Potent In Vitro and Intracellular Inhbitory Activities against Mycobacterium tuberculosis

Multidrug-resistant tuberculosis (MDR-TB) is often associated with poor clinical outcomes. In this study, we evaluated the potential of nosiheptide (NOS) as a new drug candidate for treating Mycobacterium tuberculosis infections, including MDR-TB. The antimicrobial susceptibility testing was perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xia, Zhu, Rui, Geng, Zhi, Kong, Yaoyao, Wang, Fen, Dong, Lingling, Zhao, Liping, Xue, Yi, Ma, Xiaochi, Huang, Hairong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769715/
https://www.ncbi.nlm.nih.gov/pubmed/36222690
http://dx.doi.org/10.1128/spectrum.01444-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769715/
https://www.ncbi.nlm.nih.gov/pubmed/36222690
http://dx.doi.org/10.1128/spectrum.01444-22

Ejemplares similares